The Diverse Consequences of FOXC1 Deregulation in Cancer

L. Niall Gilding; Tim C. P. Somervaille

doi:10.3390/cancers11020184

The Diverse Consequences of FOXC1 Deregulation in Cancer

L. Niall Gilding, Tim C. P. Somervaille

Cancer Research UK Manchester Institute

Research output: Contribution to journal › Article › peer-review

Abstract

Forkhead box C1 (FOXC1) is a transcription factor with essential roles in mesenchymal lineage specification and organ development during normal embryogenesis. In keeping with these developmental properties, mutations that impair the activity of FOXC1 result in the heritable Axenfeld-Rieger Syndrome and other congenital disorders. Crucially, gain of FOXC1 function is emerging as a recurrent feature of malignancy; FOXC1 overexpression is now documented in more than 16 cancer types, often in association with an unfavorable prognosis. This review explores current evidence for FOXC1 deregulation in cancer and the putative mechanisms by which FOXC1 confers its oncogenic effects.

Original language	English
Pages (from-to)	184
Journal	Cancers
Volume	11
Issue number	2
Early online date	5 Feb 2019
DOIs	https://doi.org/10.3390/cancers11020184
Publication status	Published - Feb 2019

Keywords

Epigenetics
transcription factor
epithelial-mesenchymal transition
metastasis
cellular reprogramming;
pioneer factor

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers11020184Licence: CC BY

http://www.mdpi.com/2072-6694/11/2/184

Cite this

@article{caa3351054d24a57a6e0d89f3d1f61a1,

title = "The Diverse Consequences of FOXC1 Deregulation in Cancer",

abstract = "Forkhead box C1 (FOXC1) is a transcription factor with essential roles in mesenchymal lineage specification and organ development during normal embryogenesis. In keeping with these developmental properties, mutations that impair the activity of FOXC1 result in the heritable Axenfeld-Rieger Syndrome and other congenital disorders. Crucially, gain of FOXC1 function is emerging as a recurrent feature of malignancy; FOXC1 overexpression is now documented in more than 16 cancer types, often in association with an unfavorable prognosis. This review explores current evidence for FOXC1 deregulation in cancer and the putative mechanisms by which FOXC1 confers its oncogenic effects.",

keywords = "Epigenetics, transcription factor, epithelial-mesenchymal transition, metastasis, cellular reprogramming;, pioneer factor",

author = "Gilding, {L. Niall} and Somervaille, {Tim C. P.}",

year = "2019",

month = feb,

doi = "10.3390/cancers11020184",

language = "English",

volume = "11",

pages = "184",

journal = "Cancers",

publisher = "MDPI",

number = "2",

}

TY - JOUR

T1 - The Diverse Consequences of FOXC1 Deregulation in Cancer

AU - Gilding, L. Niall

AU - Somervaille, Tim C. P.

PY - 2019/2

Y1 - 2019/2

N2 - Forkhead box C1 (FOXC1) is a transcription factor with essential roles in mesenchymal lineage specification and organ development during normal embryogenesis. In keeping with these developmental properties, mutations that impair the activity of FOXC1 result in the heritable Axenfeld-Rieger Syndrome and other congenital disorders. Crucially, gain of FOXC1 function is emerging as a recurrent feature of malignancy; FOXC1 overexpression is now documented in more than 16 cancer types, often in association with an unfavorable prognosis. This review explores current evidence for FOXC1 deregulation in cancer and the putative mechanisms by which FOXC1 confers its oncogenic effects.

AB - Forkhead box C1 (FOXC1) is a transcription factor with essential roles in mesenchymal lineage specification and organ development during normal embryogenesis. In keeping with these developmental properties, mutations that impair the activity of FOXC1 result in the heritable Axenfeld-Rieger Syndrome and other congenital disorders. Crucially, gain of FOXC1 function is emerging as a recurrent feature of malignancy; FOXC1 overexpression is now documented in more than 16 cancer types, often in association with an unfavorable prognosis. This review explores current evidence for FOXC1 deregulation in cancer and the putative mechanisms by which FOXC1 confers its oncogenic effects.

KW - Epigenetics

KW - transcription factor

KW - epithelial-mesenchymal transition

KW - metastasis

KW - cellular reprogramming;

KW - pioneer factor

U2 - 10.3390/cancers11020184

DO - 10.3390/cancers11020184

M3 - Article

VL - 11

SP - 184

JO - Cancers

JF - Cancers

IS - 2

ER -

The Diverse Consequences of FOXC1 Deregulation in Cancer

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Fingerprint

Cite this